

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/48112 A2

(51) International Patent Classification⁷: **C07D 215/22**,
471/04, 495/04, A61K 31/47, 31/435, A61P 15/00, 35/00

(21) International Application Number: PCT/US01/48119

(22) International Filing Date:
11 December 2001 (11.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/254,827 12 December 2000 (12.12.2000) US
09/992,785 14 November 2001 (14.11.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **ORTHO-MCNEIL PHARMACEUTICAL, INC.** [US/US]; US Route 202, Raritan, NJ 08869-0602 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

(72) Inventors: **SUI, Zhihua**; 11 Running Brook Circle, Flemington, NJ 08822 (US). **MACIELAG, Mark**; 8 Seneca Trail, Branchburg, NJ 08876 (US). **LANTER, James, C.**; 3 Albion Court, Flemington, NJ 08822 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: **JOHNSON, Philip, S. et al.**; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(54) Title: **7-HETEROCYCLYL QUINOLINE AND THIENO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE**

(57) Abstract: The present invention is directed to novel 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives of the general formula (I) or (II), wherein all variables are as herein defined, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions associated with gonadotropin releasing hormone (GnRH). The compounds of the invention are antagonists of GnRH, useful in the treatment of the infertility, prostate cancer, benign prostate hyperplasia (BPH) and as contraceptives.

WO 02/48112 A2

7-HETEROCYCLYL QUINOLINE AND THIENO[2,3-*b*]PYRIDINE
DERIVATIVES USEFUL AS ANTAGONISTS OF GONADOTROPIN
RELEASING HORMONE

5

FIELD OF THE INVENTION

The present invention is directed to novel 7-heterocyclyl quinoline and thieno[2,3-*b*]pyridine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions associated with gonadotropin releasing hormone (GnRH). The compounds of the invention are antagonists of GnRH, useful in the treatment of infertility, prostate cancer, benign prostate hyperplasia (BPH), and useful as contraceptives.

15

BACKGROUND OF THE INVENTION

Gonadotropin-releasing hormone (GnRH), also referred to as luteinizing hormone-releasing hormone (LHRH) is a linear decapeptide amide, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂, originally isolated from porcine (Matsuo, H., et. al., *Biochem. Biophys. Res. Commun.* **1972**, 43, 1334-1339) and ovine (Burgus, R., et. al., *PNAS, USA*, **1972**, 69, 278-282) sources. GnRH plays a key role in the reproductive system. The hormone is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH released from the pituitary gland is primarily responsible for the regulation of gonadal steroid production in both males and females, whereas FSH regulates spermatogenesis in males and follicular development in females.

25

GnRH-based therapies using peptidic GnRH agonists and antagonists have been shown effective in the treatment of conditions associated with LH/FSH release, such as endometriosis, uterine fibroids, polycystic ovarian disease, precocious puberty and some gonadal steroid-dependent neoplasia,

30

particularly prostate cancer, breast cancer and ovarian cancer. GnRH agonists and antagonists are also useful in the treatment of fertility and as a contraceptive in both males and females.

5 Although the compounds of the present invention are useful primarily for the treatment of disorders and conditions associated with the reproductive system, they may also be useful for the treatment of other GnRH mediated disorders and conditions including pituitary gonadotrope adenomas, sleep disorders, benign prostate hyperplasia, and prostate cancer.

10

 Peptide-like GnRH antagonists are known, for example, derivatives of straight-chain peptides (US Patent 5140009 and 517835), cyclic hexapeptide derivatives (Japanese Patent Application Laid-open No. 61(1986)-191698), and bicyclic peptide derivatives (J. Med. Chem. 1993, 36, 3265). However, due to a lack of bioavailability, these compounds are limited to intravenous and subcutaneous administration.

15

 Recently, small molecule, non-peptide GnRH antagonists have been disclosed. Kato, et al., in EP0679642 disclose isochroman derivatives which have gonadotropin releasing hormone receptor antagonizing activity, as well as calcium-antagonizing and monoamine-uptake inhibiting activities.

20

 Ohkawa et al., in WO96/38438 disclose tricyclic diazepine derivatives which have gonadotropin releasing hormone receptor antagonist activity. Ohkawa et al., in WO95/29900 disclose condensed heterocyclic compounds which have GnRH receptor antagonistic action and / or an action of improving sleep disturbances.

25

 Furuya et al., in WO97/14682 disclose quinolone derivatives as GnRH antagonists, useful as prophylactic or therapeutic agents for the prevention or treatment of sex hormone dependent disease.


30

Goulet et al., in WO97/44037 and in WO97/44041, Goulet et al., in WO97/44321 and Goulet et al., in WO97/44339 disclose non-peptide antagonists of GnRH useful for the treatment of a variety of sex-hormone related conditions in men and women. Goulet et al., in WO97/21703 and in
 5 WO97/21707 disclose non-peptide antagonists of GnRH useful for the treatment of a variety of sex-hormone related conditions in men and women.

Furuya et al., in WO95/28405 disclose bicyclic thiophene derivatives with gonadotropin releasing hormone receptor antagonizing activity. Furuya et al., in WO97/41126 disclose 4,7-dihydro-4-oxothieno[2,3-b]pyridine derivatives
 10 having GnRH antagonistic activity. Furuya, et al., in WO97/14697 disclose thieno[2,3-b]pyridine derivatives as GnRH antagonists.

SUMMARY OF THE INVENTION

The present invention is directed to a compound of formula (I) or (II):



wherein

L¹ is selected from the group consisting of CH₂, CH(CH₃) and C(CH₃)₂;

R¹ and R² are independently selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the aryl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, nitro, NH₂, NH(alkyl), N(alkyl)₂, -C(O)-alkyl, -C(O)-aryl or -C(O)-cycloalkyl;

X is selected from the group consisting of O, S and NR^A; where R^A is selected from hydrogen, alkyl, aryl or aralkyl;

R^4 is selected from the group consisting of $-C(O)-R^B$, $-C(O)O-R^B$, $-C(O)NH_2$, $-C(O)-NHR^B$, $-C(O)-N(R^B)_2$, and $-C(O)NHNH_2$;

wherein R^B is selected from the group consisting of alkyl, aryl, aralkyl and cycloalkyl;

5 alternatively X is N and is taken together with R^4 to form a ring structure selected from the group consisting of pyrazolyl, dihydropyrazolyl, isoxazolinyl and dihydropyrimidinyl; wherein the ring structure is optionally substituted with one or more R^C ;

10 wherein each R^C is independently selected from the group consisting of oxo, alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl, -O-aryl, aralkyl and -O-aralkyl;

L^2 is selected from the group consisting of alkyl;

R^3 is selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, cyano or sulfonamido;

15 R^5 is selected from the group consisting of halogen, cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, cyano or sulfonamido;

20 provided that when X is O, then R^5 is selected from the group consisting of heteroaryl or heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, cyano or sulfonamido; and pharmaceutically acceptable salts, esters and pro-drugs thereof.

25 In an aspect of the present invention is the compound 4,7-dihydro-2-(4-methoxyphenyl)-7-[(2-methoxyphenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-*b*]pyridine-5-carboxylic

acid hydrazide, and pharmaceutically acceptable salts, esters and prodrugs thereof.

5 Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above. An illustration of the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds
10 described above and a pharmaceutically acceptable carrier.

Exemplifying the invention are methods of treating disorders or diseases which respond to antagonism of GnRH, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of any of the
15 compounds or pharmaceutical compositions described above.


An example of the invention is a method for treating infertility, prostate cancer or benign prostate hyperplasia (BPH), in a subject in need thereof comprising administering to the subject an effective amount of any of the
20 compounds or pharmaceutical compositions described above.

A further example of the invention is a method of female or male contraception, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of any of the compounds or
25 pharmaceutical compositions described above.

Yet another example of the invention is the use of any of the compounds described herein in the preparation of a medicament for treating: (a) infertility, (b) prostate cancer, (c) benign prostate hyperplasia (BPH) or for (d)
30 contraception, in a subject in need thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a compound of formula (I) or (II):



wherein L^1 , R^1 , R^2 , X , R^4 , L^2 , R^3 and R^5 are as previously described, useful in the treatment of disorders or diseases which respond to antagonism of the GnRH such as infertility, prostate cancer, benign prostate hyperplasia (BPH), and the like. The compounds of the present invention are further useful as contraceptives.

In one embodiment of the present invention are compounds of the formula (I) wherein

L^1 is CH_2 ;

R^1 and R^2 are independently selected from the group consisting of lower alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one to two substituents independently selected from halogen, lower alkyl, lower alkoxy, nitro, NH_2 , NH (lower alkyl) or N (lower alkyl) $_2$;

X is O ;

R^4 is selected from the group consisting of $-C(O)O$ -alkyl, $-C(O)O$ -aryl and $-C(O)NHNH_2$;

alternatively X is N and is taken together with R^4 to form a ring structure selected from the group consisting of pyrazolyl, pyrazolinyl, dihydropyridyl and dihydropyrimidyl, wherein the ring structure is optionally substituted with one to two substituents independently selected from oxo, lower alkyl, lower alkoxy, aryl, $-O$ -aryl, aralkyl or $-O$ -aralkyl;

L^2 is selected from the group consisting of lower alkyl;

R^3 is selected from the group consisting of aryl; wherein the aryl group is optionally substituted with one to two substituents independently selected from halogen, lower alkyl, lower alkoxy, nitro, NH_2 , $NH(\text{lower alkyl})$, $N(\text{lower alkyl})_2$, cyano or sulfonamido;

R^5 is selected from the group consisting of halogen, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocycloalkyl wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl is optionally substituted with one to two substituents independently selected from halogen, lower alkyl, lower alkoxy, nitro, NH_2 , $NH(\text{lower alkyl})$, $N(\text{lower alkyl})_2$, cyano or sulfonamido;

provided that when X is O, then R^5 is selected from the group consisting of heteroaryl or heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl group is optionally substituted with one to two substituents selected from halogen, lower alkyl, lower alkoxy, nitro, NH_2 , $NH(\text{lower alkyl})$, $N(\text{lower alkyl})_2$, cyano or sulfonamido;

and pharmaceutically acceptable salts, esters and pro-drugs thereof.

In another embodiment of the present invention are compounds of the formula (I) or (II) wherein X is S and R^5 is selected from the group consisting of heteroaryl or heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(\text{alkyl})$, $N(\text{alkyl})_2$, cyano or sulfonamido;

In a further embodiment of the present invention are compounds of the formula (I) or (II) wherein X is NR^A or alternatively X is N and is taken together with R^4 to form a ring structure selected from the group consisting of pyrazolyl, dihydropyrazolyl, isoxazoliny and dihydropyrimidinyl; wherein the ring structure is optionally substituted with one or more R^C , wherein R^C is as defined above.

In a particularly preferred embodiment of the present invention are compounds of the formula (I) and (II) as listed in Tables 1 and 2.

TABLE I








				
ID #	X	R ⁴	R ⁵	Mol. Wt. (M ⁺)
1	O	-C(O)OCH ₂ CH ₃	3-thienyl	559
2	O	-C(O)OCH ₂ CH ₃	2-benzofuryl	593
3			bromo	524
4			2-benzofuryl	561
5			2-benzofuryl	651
6			2-benzofuryl	589

TABLE II

			
ID #	X	R ⁴	Mol Wt (M ⁺¹)
7	O	-C(O)-NH-NH ₂	569
8			551

As used herein, "halogen" shall mean chlorine, bromine, fluorine and iodine.

5

As used herein, the term "alkyl" whether used alone or as part of a substituent group, includes straight and branched chains comprising one to ten carbon atoms. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and the like. Unless otherwise noted, "lower" when used with alkyl means a carbon chain composition of 1-6 carbon atoms.

10

As used herein, unless otherwise noted, "alkoxy" shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like. Unless otherwise noted, "lower" when used with alkoxy means an oxygen ether radical of the above described straight or branched carbon chain alkyl group wherein the alkyl is of 1-6 carbon atoms.

15

As used herein, unless otherwise noted, "aryl" shall refer to carbocyclic aromatic groups such as phenyl, naphthyl, and the like.

5 As used herein, unless otherwise noted, "aralkyl" shall mean any lower alkyl group substituted with an aryl group such as phenyl, naphthyl and the like. For example, benzyl, phenylethyl, phenylpropyl, naphthylmethyl, and the like.

10 As used herein, unless otherwise noted, "cycloalkyl" shall mean any three to eight membered, monocyclic, saturated, carbocyclic ring structure including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

As used herein, unless otherwise noted, "heteroaryl" shall denote any five or six membered monocyclic aromatic ring structure containing at least one heteroatom selected from the group consisting of O, N and S, optionally
15 containing one to three additional heteroatoms independently selected from the group consisting of O, N and S; or a nine or ten membered bicyclic aromatic ring structure containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to four additional heteroatoms independently selected from the group consisting of O, N and S. The heteroaryl
20 group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.

Examples of suitable heteroaryl groups include, but are not limited to, pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, purazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranal, furazanyl, indoliziny, indolyl, isoindoliny, indazolyl, benzofuryl, benzothienyl, benzimidazolyl, benzthiazolyl, puriny, quinoliziny, quinoliny, isoquinoliny, isothiazolyl, cinnoliny, phthalazinyl, quinazoliny, quinoxaliny, naphthyridiny, pteridiny, and the like.

30

As used herein, the term "heterocycloalkyl" shall denote any five to seven membered monocyclic, saturated, partially unsaturated or partially aromatic ring


structure containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to three additional heteroatoms independently selected from the group consisting of O, N and S; or a nine to ten membered saturated, partially unsaturated or partially aromatic bicyclic ring system containing at least one heteroatom selected from the group consisting of O, N and S, optionally containing one to four additional heteroatoms independently selected from the group consisting of O, N and S. The heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.

Examples of suitable heterocycloalkyl groups include, but are not limited to, pyrrolinyl, pyrrolidinyl, dioxalanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, indolinyl, chromenyl, 3,4-methylenedioxyphenyl and 2,3-dihydrobenzofuryl and the like.

When a particular group is "substituted" (e.g., cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl), that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three substituents, most preferably from one to two substituents, independently selected from the list of substituents.

With reference to substituents, the term "independently" means that when more than one of such substituents is possible, such substituents may be the same or different from each other.

Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. Thus, for example, a "phenylalkylaminocarbonylalkyl" substituent refers to a group of the formula



Names for chemical entities of the present invention may be generated using nomenclature rules known in the art or may alternatively be generated using commercial chemical naming software, for example ACD/Index Name (Advanced Chemistry Development, Inc., Toronto, Ontario)

For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include the following:

acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate,

stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate.

5 The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible *in vivo* into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a
10 compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

15 Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are
20 encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the
25 scope of this invention.

The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

30 The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or

medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.


5 As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

10 Abbreviations used in the specification, particularly the Schemes and Examples, are as follows:

	α MEM	=	Minimum Essential Medium
	DCM	=	Dichloromethane
	DIPEA	=	Diisopropylethylamine
15	DMF	=	N,N-Dimethylformamide
	DME	=	Dimethoxyethane
	DMSO	=	Dimethylsulfoxide
	Et ₃ N	=	Triethylamine
	EtOAc	=	Ethyl Acetate
20	LHMDS	=	Lithium hexamethyldisilazide
	MeOH	=	Methanol
	NBS	=	1-bromo-2,5-pyrrolidinedione
	Ph	=	Phenyl
	RT or rt	=	Room temperature
25	TEA	=	Triethylamine
	THF	=	Tetrahydrofuran

Compounds of the general formula (I) wherein X is O, may be prepared according to the process outlined in Scheme 1.

30



Scheme 1

5

More particularly, a compound of formula (III), a known compound or compound prepared by known methods, wherein Q is bromo or iodo, is reacted with a suitably substituted compound of formula (IV), in the presence of a base such as potassium carbonate, TEA, NaOH, NaH, DIPEA, and the like, in an organic solvent such as THF, DMF, DCM, and the like, to yield the corresponding compound of formula (V).

10

15


The compound of formula (V) is reacted with a brominating agent such as 70% NBS, and the like, in an organic solvent such as THF, DMF, DCM, and the like, to yield the corresponding compound of formula (VI).

The compound of formula (VI) is reacted with a suitably substituted amine of formula (VII), in the presence of a base such as TEA, DIPEA, and the

like, in an organic solvent such as THF, DMF, and the like, to yield the corresponding compound of formula (VIII).

The compound of formula (VIII) is reacted with a suitably substituted boronic acid of formula (IX), in the presence of a catalyst such as palladium tetrakis(triphenylphosphine) ($\text{Pd}(\text{PPh}_3)_4$), and the like, in the presence of a base such as NaCO_3 , NaOH , and the like, in an organic solvent such as THF, DMF, dioxane, and the like, optionally in a mixture with water, to yield the corresponding compound of formula (Ia).



Compounds of formula (I) wherein X is S may be prepared according to the process outlined in Scheme 2.




Scheme 2

Specifically, a suitably substituted compound of formula (Ia), prepared as in Scheme 1, is reacted with a sulfonating agent such as P_4S_{10} , Lawesson's reagent, and the like, in an organic solvent such as pyridine, toluene, xylene, and the like, at an elevated temperature in the range of about 60-140°C, to yield the corresponding compound of formula (Ib).

Compounds of formula (I) wherein X is N and is taken together with R^4 to

form  or , wherein R^D is selected from the group consisting of alkyl, aryl and aralkyl, may be prepared according to the process outlined in Scheme 3.



Scheme 3

5

More particularly, a suitably substituted compound of formula (Ib), prepared as in Scheme 2, is reacted with a compound of formula (X), in an organic solvent such as DMF, DMSO, and the like, at an elevated temperature in the range of about 80-110°C, to yield the corresponding compound of formula (Ic).

10


The compound of formula (Ic) is optionally further reacted with a compound of formula (XI), wherein R^D is selected from the group consisting of alkyl, aryl and aralkyl, in the presence of a strong base such as LHMDs, NaH, potassium t-butoxide, and the like, to yield the corresponding compound of formula (Id).

15

Alternatively, the compound of formula (Ic) may be further reacted according to known methods to introduce one or more substituents on the pyrazolyl group.

20

Compounds of formula (I) wherein X is NR^{A} may be prepared according to the process outlined in Scheme 4.




Scheme 4

More particularly, a suitably substituted compound of formula (Ib), prepared as in Scheme 2, is reacted with a suitably substituted amine of formula (XII), in an organic solvent such as DMF, DMSO, and the like, preferably at an elevated temperature in the range of about 60-120°C, to yield the corresponding compound of formula (Ie).

Compounds of formula (I) wherein X is N and is taken together with R^4 to form a ring structure selected from the group consisting of dihydropyrazolyl, isoxazolinyll and dihydropyrimidinyl may be prepared by methods known to those skilled in the art.


For example, compounds of formula (I) wherein X is N and is taken




together with R^4 to form dihydropyrazolyl () may be prepared by reacting a suitably substituted compound of formula (Ia), wherein X is O and R^4 is an ester of the formula $-\text{CO}_2\text{R}^{\text{B}}$, prepared as in Scheme 1, with a suitable reducing agent, to yield the corresponding compound wherein R^4 is an aldehyde of the formula $-\text{C}(\text{O})\text{H}$, subsequently reacting the R^4 aldehyde with benzylcarbazate to yield the corresponding compound wherein R^4 is hydrazone ($-\text{CHNNH}-\text{C}(\text{O})\text{O}-\text{benzyl}$), reducing the R^4 hydrazone with hydrogen gas, in the presence of a catalyst such as palladium hydroxide, to yield the corresponding


compound wherein R^4 is hydrazine ($-\text{CH}_2\text{NHNH}_2$), and then treating the R^4 hydrazine with a dehydration reagent such as P_2O_5 , at an elevated temperature to yield the corresponding dihydropyrazole substituted compound of formula (I).


5 Compounds of formula (I) wherein X is N and is taken together with R^4 to





form isoxazolinyl () may be prepared by subjecting a suitably substituted compound of formula (Ia), wherein X is O and R^4 is an ester of the formula $-\text{CO}_2\text{R}^B$, prepared as in Scheme 1, to saponification to convert the R^4 ester group to the corresponding carboxy group ($-\text{CO}_2\text{H}$) and then treating the R^4 carboxy group with a suitable reducing agent, to yield the corresponding compound wherein R^4 is an alcohol of the formula $-\text{CH}_2\text{OH}$, converting the X is O carbonyl group to the corresponding X is S thiocarbonyl group, converting the thiocarbonyl group to the corresponding hydroxyamine where X is N-OH, and then affecting ring closure of the X hydroxyamine and R^4 alcohol with a dehydrating agent such as P_2O_5 , at an elevated temperature to yield the corresponding isoxazolinyl substituted compound of formula (I).


Compounds of formula (I) wherein X is N and is taken together with R^4 to




form dihydropyrimidinyl () or oxo-substituted dihydropyrimidinyl




20 () may be prepared by reacting a suitably substituted compound of formula (Ia), wherein R^4 is an ester of the formula $-\text{CO}_2\text{R}^B$, prepared as in Scheme 1, with urea, thiourea, guanidine or a suitably substituted alkyl or aryl amidine, in an organic solvent, at an elevated temperature to yield the




corresponding oxo-substituted dihydropyrimidinyl (), thio-substituted



dihydropyrimidinyl (), imino-substituted dihydropyrimidinyl




() or alkyl or aryl substituted dihydropyrimidinyl ()




5 substituted compound of formula (I). The oxo-substituted dihydropyrimidinyl substituted compound of formula (I) may be further optionally, alkylated according to the process described in Scheme 3, to yield the corresponding dihydropyrimidinyl substituted compound of formula (I). Similarly, the thio- or imino-substituted dihydropyrimidinyl substituted compound of formula (I) may be further, optionally reacted according to known methods to displace the thio group (=S) or modify the imino group (=NH), respectively.

10

Compounds of formula (II), wherein R^4 is $-C(O)O-R^6$, X is S or X is N



and is taken together with R^4 to form , may be prepared according to the process outlined in Scheme 5.



Scheme 5

5 More particularly, a compound of formula (X), a known compound or compound prepared by known methods, is reacted with a sulfonating agent such as P_4S_{10} , Lawesson's Reagent, and the like, in the presence of an organic base such as pyridine, TEA, Hünig's base (DIEA), and the like, at an elevated temperature in the range of about 60-120°C, preferably at about reflux

10 temperature, to yield the corresponding compound of formula (IIa).

The compound of formula (IIa) may be optionally further reacted with $\text{H}_2\text{N}-\text{NH}_2$, in an organic solvent such as DMF, DMSO, and the like, at an elevated temperature in the range of about 80-110°C, to yield the

15 corresponding compound of formula (IIb).

The compound of formula (IIb) may be further, optionally reacted according to known methods to introduce one or more substituents on the pyrazolyl group.

Compounds of formula (II) wherein X is N and taken together with R⁴ to form a ring selected from the group consisting of dihydropyrazolyl, isoxazolinyll and dihydropyrimidinyl, may be similarly prepared according to the processes described above, with appropriate substitution of a compound of formula (X) for the compound of formula (Ia).

Compounds of formula (II) wherein X is selected from the group consisting of O, S and NR^A, may be prepared from the corresponding compound of formula (X), by methods known to those skilled in the art.

For example, compounds of formula (II) wherein X is O and R⁴ is other than -C(O)OR⁶ may be prepared by converting the R⁴ ester group on a suitably substituted compound of formula (X) to the corresponding R⁴ carboxy group and then using known quinolone chemistry to convert the R⁴ carboxy group to the desired R⁴ functionality.

Compounds of formula (II) wherein X is S and R⁴ is other than -C(O)OR⁶, may similarly be prepared by converting the -C(O)OR⁶ ester on the compound of formula (X) to the desired R⁴ group as described above and then converting the X is O, (carbonyl group) to the corresponding X is S (thiocarbonyl group) by reacting with a sulfonating agent, as described in Scheme 5.

Compounds of formula (II) wherein X is NR^A and R⁴ is other than -C(O)OR⁶, may similarly be prepared by converting the -C(O)OR⁶ ester on the compound of formula (X) to the desired R⁴ group as described above and then converting the X is O (carbonyl group) to the corresponding X is NR^A (amine group) by reacting with a suitably substituted amine, as described in Scheme 4.

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.

EXAMPLE 1

7-Bromo-6-bromomethyl-1-(2,6-difluorobenzyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethylester

A mixture of 7-bromo-1-(2,6-difluorobenzyl)-1,4-dihydro-6-methyl-4-oxoquinoline-3-carboxylic acid ethyl ester (3.5 g, 8 mmol), prepared according to the procedure outlined in PCT application WO97/14682, Reference Example 3, NBS (1.5 g, 8.4 mmol) and 2,2'-azobisisobutyronitrile (AIBN, 100 mg) in DCM (200 mL) was stirred at reflux for 4 h. Additional NBS (750 mg) was added and the mixture was refluxed for 4 h. Column chromatography (hexanes:ethyl acetate = 3:7) yielded the product as a white solid.

Yield: 2.95 g (72%)

m.p. 184-187°C;

^1H NMR (CDCl_3), δ 1.41 (t, J = 8 Hz, 3 H), 4.40 (q, J = 8 Hz, 2 H), 4.66 (s, 2 H), 5.36 (s, 2H), 7.03 (m, 2 H), 7.39 (m, 1 H), 7.92 (s, 1 H), 8.54 (s, 1 H), 8.68 (ds, 1 H);

MS (m/z): 514 (MH^+).

EXAMPLE 2

6-(N-Benzyl-N-methylaminomethyl)-7-bromo-1-(2,6-difluorobenzyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethylester

A mixture of 7-bromo-6-bromomethyl-1-(2,6-difluorobenzyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethyl ester (110 mg, 0.21 mmol), methylbenzylamine (31 mg, 0.26 mmol) in DIPEA (0.045 mL) and DMF (15 mL) was stirred at room temperature for 16 h. Ethyl acetate and water were added. The organic phase was separated and washed with water, dried with MgSO_4 . The solvent was evaporated and the residue dried under vacuum to yield the product as a white solid.

Yield: 120 mg (100%)

^1H NMR (CDCl_3), δ 1.41 (t, J = 8 Hz, 3 H), 2.17 (s, 3 H), 3.62 (s, 2 H), 3.67 (s, 2 H), 4.40 (q, J = 8 Hz, 2 H), 5.36 (s, 2H), 7.03 (m, 2 H), 7.25-7.39 (m, 6 H), 7.88 (s, 1 H), 8.59 (s, 1 H), 8.67 (ds, 1 H);

MS (m/z): 555 (MH^+).

5

EXAMPLE 3

6-(N-Benzyl-N-methylaminomethyl)-7-(benzofuran-2-yl)-1-(2,6-difluorobenzyl)-
1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethylester

10

Compound #2

A mixture of 7-bromo-6-bromomethyl-1-(2,6-difluorobenzyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethyl ester (278 mg, 0.5 mmol), benzofuran-2-boronic acid (97 mg, 0.6 mmol), tetrakis(triphenylphosphine)palladium(0) (69 mg, 0.06 mmol) and 2M sodium carbonate (414 mg, 3 mmol) in DME (20 mL) was heated at reflux for 16 h. Ethyl acetate and water were added. The organic phase was separated and washed with water and dried with MgSO_4 . Column chromatography (ethyl acetate) yielded the product as a yellow solid.

15

Yield: 55 mg (19%)

^1H NMR (CDCl_3), δ 1.44 (t, J = 8 Hz, 3 H), 2.17 (s, 3 H), 3.63 (s, 2 H), 3.90 (s, 2 H), 4.42 (q, J = 8 Hz, 2 H), 5.49 (s, 2H), 7.00 (m, 2 H), 7.22-7.81 (m, 11 H), 8.23 (s, 1 H), 8.62 (s, 1 H), 8.76 (ds, 1 H);

20

MS (m/z): 593 (MH^+).

25

EXAMPLE 4

2,5-dihydro-7-(4-methoxyphenyl)-5-[(2-methoxyphenyl)methyl]-8-
[[methyl(phenylmethyl)amino]methyl]-3*H*-pyrazolo[3,4-*d*]thieno[2,3-*b*]pyridin-3-one

Compound #8

To a solution of 4,7-dihydro-2-(4-methoxy-phenyl)-7-[(2-methoxyphenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-*b*]pyridine-5-carboxylic acid, ethyl ester (prepared according to the

30

procedure described by Furuya, S, et al., in PCT Application WO95/28405),
(387 mg, 0.66 mmol) in pyridine (3 mL) was added P₄S₁₀. The reaction flask
was flushed with argon and stirred at reflux for 5 hours. The solvent was
removed and the product purified by flash chromatography to yield the
5 corresponding thiocarbonyl.

The thiocarbonyl (118 mg, 0.19 mmol) was dissolved in dry DMF (0.25
mL) and treated with hydrazine monohydrate (0.02 mL, 0.42 mmol). The
resulting solution was heated to 80°C for 2 hours, the mixture was cooled and
purified by flash chromatography (0-10% MeOH/CHCl₃). The product was
10 converted to its hydrochloride salt by treating with HCl to yield the product as a
yellow powder.

Yield: 7.5 mg

MS (m/z) 551 (MH⁺).

15

EXAMPLE 5

2,5-Dihydro-7-(benzofuran-2-yl)-8-[[methyl(phenylmethyl)amino]methyl]-5-[(2,6-
difluorophenyl)methyl]-3H-pyrazolo[4,3-c]quinolin-3-one

Compound #4

To a solution of 7-(benzofuran-2-yl)-8-[[methyl(phenylmethyl)-amino]-
methyl]-5-[(2,6-difluorophenyl)methyl]-3-quinolinecarboxylic acid ethyl ester,
(500 mg, 0.84 mmol) in pyridine (5 mL) was added P₄S₁₀ (240 mg, 0.65 eq).
The reaction flask was flushed with argon and stirred at reflux for 2 hours,
cooled to 100°C and poured into water (100 mL). The product was extracted
25 into chloroform, dried (MgSO₄) and concentrated to yield a red-brown solid.

The solid (337 mg, 0.55 mmol) was dissolved in dry DMF (5 mL) and
treated with hydrazine monohydrate (60 mg, 1.1 mmol). The resulting mixture
was warmed to 100°C for 3 hours, the mixture was cooled and poured onto
water. The resulting yellow precipitate was collected by filtration and dried to
30 yield the product.

Yield: 149 mg

^1H NMR (CDCl_3) δ 2.09 (s, 3H), 3.57 (s, 2H), 3.86 (s, 2H), 5.84 (s, 2H), 7.18-7.49 (m, 12H), 7.66-7.77 (m, 2H), 8.16 (s, 1H), 8.33 (s, 1H), 8.95 (s, 1H).

5

EXAMPLE 6

7-(Benzofuran-2-yl)-3-[(phenylmethyl)oxy]-5-[(2,6-difluorophenyl) methyl]-8-
[[methyl(phenylmethyl)amino]methyl]-5H-pyrazolo[4,3-c]quinoline
Compound #5

A solution of 2,5-dihydro-7-(benzofuran-2-yl)-8-
10 [[methyl(phenylmethyl)amino]methyl]-5-[(2,6-difluorophenyl)methyl]-3H-
pyrazolo[4,3-c]quinolin-3-one (120 mg, 0.21 mmol) in dry DMF (5 mL) was
treated with a solution of lithium hexamethyldisilazide (0.25 mL, 0.25 mol, 1.0
M) in tetrahydrofuran (THF). Benzyl bromide (40 mg, 0.22 mmol) was
introduced via syringe and the mixture was stirred overnight. One equivalent
15 hydrochloric acid in ether was added and the solvent evaporated to yield the
corresponding hydrochloride salt product as a yellow solid.

Yield: 47 mg

^1H NMR (CDCl_3) δ 2.08 (s, 3H), 3.55 (s, 2H), 3.87 (s, 2H), 5.13 (s, 2H),
5.88 (s, 2H), 7.12-7.51 (m, 16 H), 7.66-7.70 (m, 2H), 8.16 (s, 1H), 8.37 (s, 1H),
20 9.10 (s, 1H).

EXAMPLE 7

6-(N-Benzyl-N-methylaminomethyl)-7-(thien-3-yl)-1-(2,6-difluorobenzyl)-1,4-
25 dihydro-4-oxoquinoline-3-carboxylic acid ethyl ester
Compound #1

Following the procedure described in Example 3, the compound
prepared in Example 2 (6-(N-Benzyl-N-methylaminomethyl)-7-bromo-1-(2,6-
difluorobenzyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethylester) (150
30 mg, 0.27 mmol) was reacted with thiophene-3-boronic acid (38.4 mg, 0.30
mmol), to yield the product as a yellow solid.

Yield: 48 mg

MS(m/z) 559 (MH⁺).

EXAMPLE 8

5 2,5-Dihydro-7-bromo-8-[[methyl(phenylmethyl)amino]methyl]-5-[(2,6-difluorophenyl)methyl]-3H-pyrazolo[4,3-c]quinolin-3-one

Compound #3

Following the procedure described in Example 4, 6-(N-benzyl-N-methylaminomethyl)-7-bromo-1-(2,6-difluorobenzyl)-1,4-dihydro-4-
10 oxoquinoline-3-carboxylic acid ethyl ester (0.6g, 1.1 mmol) was converted to the title compound and isolated as the corresponding hydrochloride salt, as a yellow powder.

Yield: 0.15 g

MS (m/z) 524 (MH⁺)

15

EXAMPLE 9

7-(Benzofuran-2-yl)-3-ethoxy-5-[(2,6-difluorophenyl)methyl]-8-
20 [[methyl(phenylmethyl)amino]methyl]-5H-pyrazolo[4,3-c]quinoline HCl

Compound #6

Following the procedure described in Example 6, 2,5-dihydro-7-(benzofuran-2-yl)-8-[[methyl(phenylmethyl)amino]methyl]-5-[(2,6-difluorophenyl)methyl]-3H-pyrazolo[4,3-c]quinolin-3-one (0.05 g, 0.09 mmol)
25 was reacted with ethyl iodide (0.018 g, 0.116 mmol) to yield the title compound, which was isolated as its corresponding hydrochloride salt, as a yellow powder.

Yield: 0.05 g

MS (m/z) 589 (MH⁺).

EXAMPLE 10

4,7-Dihydro-2-(4-methoxyphenyl)-7-[(2-methoxyphenyl)methyl]-3-
[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-b]pyridine-5-carboxylic
acid, hydrazide bis-hydrochloride

5

Compound #7

To a solution of 4,7-dihydro-2-(4-methoxyphenyl)-7-[(2-methoxyphenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-b]pyridine-5-carboxylic acid, ethyl ester (57 mg, 0.097 mmol) in ethyl alcohol (2 mL) was added hydrazine (0.030 mL, 0.096 mmol). The mixture was
10 heated to reflux for 6 hours and concentrated *in vacuo*. Trituration of the residue with diethyl ether and collection of the solid by precipitation yielded the product as a pale yellow solid.

Yield: 38 mg

MS (m/z) 569 (MH⁺).

15

EXAMPLE 11

GnRH Receptor Binding Assay

A homogenate prepared from an equal mixture of female and male rat
20 pituitaries was used as the source of the membrane-bound GnRH receptor. The receptor was allowed to interact in solution with [¹²⁵I]-histrelin alone or in combination with a competitive ligand (the compound being tested). The bound radiolabeled ligand was separated from the free (unbound) radiolabeled ligand by filtration through glass filter mats using a 96-well plate harvesting system
25 (Tomtec Mach II 96). In the absence of a competitive ligand, a maximum amount of radiolabeled ligand is bound to the receptor and trapped by the glass filter mats. When an unlabelled ligand that can compete for the receptor site is present, the amount of radiolabeled ligand bound to the receptor and trapped on the filter mat is proportionally reduced depending on the concentration of the
30 competitor and on the strength of the competitor's affinity for the receptor. The amount of receptor-bound [¹²⁵I]-histrelin on the filter mat was determined using

a Wallac Betaplate™ Liquid Scintillation Counter. Binding was determined as follows:

	NSB	Non-specific binding
	B ₀	maximum concentration of compound
5	Average NSB:	(NSB1 + NSB2)/2
	Average B ₀ :	(B ₀ 1 + B ₀ 2)/2
	Corrected B ₀ :	Average B ₀ – Average NSB

% inhibition of Corrected B₀ (or maximum response) was calculated as follows:

10

$$\% \text{ Inhibition} = 100 - \left[\frac{((\text{Actual counts per minute} - \text{Average NSB})}{\text{Corrected B}_0}) * 100 \right]$$

15

EXAMPLE 12

LUCIFERASE Assay FOR GnRH

Hek 293 cells with the GnRHR gene were transfected with the hCG promoter and the luciferase reporter system. On day 1, the cells were plated at a density of 80,000 cells per well on a Poly-D-lysine pre-coated 96 well plate.

20 The plates were incubated at 37°C for 24 hours. On day 2, the spent media was decanted and replaced with fresh media. Test compounds, standard and controls were added to individual wells. All the dilutions were done in 7.5% DMSO/αMEM media. The assay was run in both agonist and antagonist format. For the antagonist format, the assay measurements were run against a

25 standard of 0.6nM Histrelin. On day 3, the levels of luciferase production were measured in a chemiluminescence assay using Enhanced Luciferase Assay Kit. The results were expressed as % Inhibition using the following formula:

	RLU	Relative Light Units, a measure of chemiluminescence
30	Agonist	[RLU value(test compound) – (Background/0.6nM Histrelin) – Background]*100
	Antagonist	(1 – [(RLU value – (Background/0.6nM Histrelin) –

Background)*100])

The calculated percentages were plotted on a graph using Graph Pad Prizm and the IC_{50}/EC_{50} values determined.

5

EXAMPLE 13

Primary Pituitary Cell Culture Assay

Male rats (between immature and adult) were sacrificed and the anterior
 10 pituitaries were collected from them. The pituitaries were dissociated and the cells were plated at a concentration of 0.33×10^6 cells/well on day 1. On day 3 the media on the cells was flushed and replaced with fresh media. The test compound was then added to the plated cells at a concentration ranging from 1 nM to 1000 nM. The plates were incubated at 37°C at 5% CO₂ for 2 days. On
 15 Day 5 the media was flushed again and replaced with fresh media. To the plates were then added test compound and 1nM GnRH. The cells were incubated for 4 hours, the media was collected by centrifuging the plates at 1200 rpm Sorvall RT7 for 10 minutes, 900μL of supernatant was pipetted from each well and dispensed to a 96 well plate. The deep well plates were covered
 20 and stored at 20°C for a day. The plates are then evaluated by ELISA (a radioimmunoassay system) to determine the concentration of lutenizing hormone in the media. The assay was repeated at varying concentrations of the test compounds to determine IC_{50} values. The IC_{50} value is defined as the concentration of test compound at which 50% inhibition was achieved.

25

Following the procedures set forth above, selected compounds of the present invention were tested, with results as listed in Table 3.

Table 3 - Biological Activity


ID #	Binding, IC_{50} (B%@30μM)	Luciferase Assay IC_{50} (μM)	Pituitary Cell Assay IC_{50} (μM)
1	32 μM	10 (antagonist)	

2	-	3.26 (antagonist)	2.43
3	16		
4	1		
5	5		
6	5		
7	1.6		1.48
8	30		

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

We Claim:

1. A compound of the formula (I)



wherein

5 L^1 is selected from the group consisting of CH_2 , $CH(CH_3)$ and $C(CH_3)_2$;

R^1 and R^2 are independently selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the aryl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, $-C(O)-alkyl$, $-C(O)-aryl$ or $-C(O)-cycloalkyl$;

X is selected from the group consisting of O, S and NR^A ; where R^A is selected from hydrogen, alkyl, aryl or aralkyl;

R^4 is selected from the group consisting of $-C(O)-R^B$, $-C(O)O-R^B$, $-C(O)NH_2$, $-C(O)-NHR^B$, $-C(O)-N(R^B)_2$, and $-C(O)NHNH_2$;

15 wherein R^B is selected from the group consisting of alkyl, aryl, aralkyl and cycloalkyl;

alternatively X is N and is taken together with R^4 to form a ring structure selected from the group consisting of pyrazolyl, dihydropyrazolyl, isoxazoliny and dihydropyrimidinyl; wherein the ring structure is optionally substituted with one or more R^C ;

20 wherein each R^C is independently selected from the group consisting of oxo, alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl, $-O-aryl$, aralkyl and $-O-aralkyl$;

L^2 is selected from the group consisting of alkyl;

25 R^3 is selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents

independently selected from halogen, alkyl, alkoxy, nitro, NH₂, NH(alkyl), N(alkyl)₂, cyano or sulfonamido;

R⁵ is selected from the group consisting of halogen, cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, nitro, NH₂, NH(alkyl), N(alkyl)₂, cyano or sulfonamido;

provided that when X is O, then R⁵ is selected from the group consisting of heteroaryl or heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, nitro, NH₂, NH(alkyl), N(alkyl)₂, cyano or sulfonamido; and pharmaceutically acceptable salts, esters and pro-drugs thereof.

2. A compound as in Claim 1 wherein

L¹ is CH₂;

R¹ and R² are independently selected from the group consisting of lower alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one to two substituents independently selected from halogen, lower alkyl, lower alkoxy, nitro, NH₂, NH(lower alkyl) or N(lower alkyl)₂;

X is O;

R⁴ is selected from the group consisting of -C(O)O-alkyl, -C(O)O-aryl and -C(O)NHNH₂;

alternatively X is N and is taken together with R⁴ to form a ring structure selected from the group consisting of pyrazolyl, pyrazolinyl, dihydropyridyl and dihydropyrimidyl, wherein the ring structure is optionally substituted with one to two substituents independently selected from oxo, lower alkyl, lower alkoxy, aryl, -O-aryl, aralkyl or -O-aralkyl;

L² is selected from the group consisting of lower alkyl;

R³ is selected from the group consisting of aryl; wherein the aryl group is optionally substituted with one to two substituents independently selected from

halogen, lower alkyl, lower alkoxy, nitro, NH_2 , $\text{NH}(\text{lower alkyl})$, $\text{N}(\text{lower alkyl})_2$, cyano or sulfonamido;

R^5 is selected from the group consisting of halogen, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocycloalkyl wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl is optionally substituted with one to two substituents independently selected from halogen, lower alkyl, lower alkoxy, nitro, NH_2 , $\text{NH}(\text{lower alkyl})$, $\text{N}(\text{lower alkyl})_2$, cyano or sulfonamido;

provided that when X is O, then R^5 is selected from the group consisting of heteroaryl or heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl group is optionally substituted with one to two substituents selected from halogen, lower alkyl, lower alkoxy, nitro, NH_2 , $\text{NH}(\text{lower alkyl})$, $\text{N}(\text{lower alkyl})_2$, cyano or sulfonamido;

and pharmaceutically acceptable salts, esters and pro-drugs thereof.

3. A compound as in Claim 1 wherein X is NR^A or X is N and is taken together with R^4 to form a ring structure selected from the group consisting of pyrazolyl, dihydropyrazolyl, isoxazolinyl and dihydropyrimidinyl; wherein the ring structure is optionally substituted with one or more R^C ; wherein each R^C is independently selected from selected the group consisting of oxo, alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl, -O-aryl, aralkyl and -O-aralkyl; and pharmaceutically acceptable salts, esters and pro-drugs thereof.

4. A compound as in Claim 2 wherein

L^1 is CH_2 ;


R^1 is selected from the group consisting of lower alkyl;

R^2 is selected from the group consisting of aralkyl;

X is O;

R^4 is selected from the group consisting of $-\text{C}(\text{O})\text{O}-(\text{lower alkyl})$;

alternatively, X is taken together with R^4 to form a group selected from



L^2 is selected from the group consisting of lower alkyl;

R^3 is selected from the group consisting of phenyl and substituted phenyl, wherein the substituents on the phenyl are one to two independently selected from halogen;

R^5 is selected from the group consisting of halogen and heteroaryl;
provided that when X is O, R^5 is heteroaryl;
and pharmaceutically acceptable salts, esters and pro-drugs thereof.

5. A compound as in Claim 4 wherein

L^1 is CH_2 ;


R^1 is methyl;

R^2 is benzyl;

X is O;

R^4 is $-C(O)O-CH_2CH_3$;

alternatively, X is taken together with R^4 to form a group selected from



L^2 is CH_2 ;

R^3 is 2,6-di-fluorophenyl;

R^5 is selected from the group consisting of bromo, 3-thienyl and 2-benzofuryl; provided that when X is O, R^5 is selected from 3-thienyl and 2-benzofuryl;

and pharmaceutically acceptable salts, esters and pro-drugs thereof.

6. A compound as in Claim 5 selected from the group consisting of

1-[(2,6-difluorophenyl)methyl]-1,4-dihydro-6-

25 [[methyl(phenylmethyl)amino]methyl]-4-oxo-7-(3-thienyl)- 3-quinolinecarboxylic acid ethyl ester;


7-(2-benzofuranyl)-1-[(2,6-difluorophenyl)methyl]-1,4-dihydro-6-

[[methyl(phenylmethyl)amino]methyl]-4-oxo-3-quinolinecarboxylic acid, ethyl ester;

7-bromo-5-[(2,6-difluorophenyl)methyl]-2,5-dihydro-8-
 [[methyl(phenylmethyl)amino]methyl]- 3*H*-pyrazolo[4,3-*c*]quinolin-3-one;
 7-(2-benzofuranyl)-5-[(2,6-difluorophenyl)methyl]-2,5-dihydro-8-
 [[methyl(phenylmethyl)amino]methyl]- 3*H*-pyrazolo[4,3-*c*]quinolin-3-one;
 5 7-(benzofuran-2-yl)-5-[(2,6-difluorophenyl)methyl]-3-[(phenylmethyl)oxy]-
 -8-[[methyl(phenylmethyl)amino]methyl]-5*H*-pyrazolo[4,3-*c*]quinoline
 7-(benzofuran-2-yl)-5-[(2,6-difluorophenyl)methyl]-3-ethoxy-8-
 [[methyl(phenylmethyl)amino]methyl]-5*H*-pyrazolo[4,3-*c*]quinoline;
 and pharmaceutically acceptable salts, esters and pro-drugs thereof.

10

7. A compound of the formula (II)



wherein

L^1 is selected from the group consisting of CH_2 , $CH(CH_3)$ and $C(CH_3)_2$;

15 R^1 and R^2 are independently selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the aryl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, $-C(O)-alkyl$, $-C(O)-aryl$ or $-C(O)-cycloalkyl$;

20 X is selected from the group consisting of O , S and NR^A ; where R^A is selected from hydrogen, alkyl, aryl or aralkyl;

R^4 is selected from the group consisting of $-C(O)-R^B$, $-C(O)O-R^B$, $-C(O)NH_2$, $-C(O)-NHR^B$, $-C(O)-N(R^B)_2$, and $-C(O)NHNH_2$;

25 wherein R^B is selected from the group consisting of alkyl, aryl, aralkyl and cycloalkyl;

alternatively X is N and is taken together with R^4 to form a ring structure selected from the group consisting of pyrazolyl, dihydropyrazolyl, isoxazoliny

and dihydropyrimidinyl; wherein the ring structure is optionally substituted with one or more R^C ;

wherein each R^C is independently selected from the group consisting of oxo, alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl, -O-aryl, aralkyl and -O-aralkyl;

L^2 is selected from the group consisting of alkyl;

R^3 is selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heterocycloalkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, cyano or sulfonamido;

R^5 is selected from the group consisting of halogen, cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, cyano or sulfonamido;

provided that when X is O, then R^5 is selected from the group consisting of heteroaryl or heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, nitro, NH_2 , $NH(alkyl)$, $N(alkyl)_2$, cyano or sulfonamido; and pharmaceutically acceptable salts, esters and pro-drugs thereof.

8. A compound as in Claim 7 wherein X is NR^A or X is N and is taken together with R^4 to form a ring structure selected from the group consisting of pyrazolyl, dihydropyrazolyl, isoxazolinyl and dihydropyrimidinyl; wherein the ring structure is optionally substituted with one or more R^C ; wherein each R^C is independently selected from the group consisting of oxo, alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl, -O-aryl, aralkyl and -O-aralkyl; and pharmaceutically acceptable salts, esters and pro-drugs thereof.

9. A compound as in Claim 7 identified as 2,5-dihydro-7-(4-methoxyphenyl)-5-[(2-methoxyphenyl)methyl]-8-

[[methyl(phenylmethyl)amino]methyl]- 3*H*-pyrazolo[3,4-*d*]thieno[2,3-*b*]pyridin-3-one; and pharmaceutically acceptable salts, esters and pro-drugs thereof.

- 5 10. A compound identified as 4,7-dihydro-2-(4-methoxyphenyl)-7-[(2-methoxyphenyl)methyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-*b*]pyridine-5-carboxylic acid hydrazide, and pharmaceutically acceptable salts, esters and prodrugs thereof.
- 10 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.
12. A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 15 13. A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 20 14. A method of treating a disorder or disease which respond to antagonism of the GnRH in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 11.
- 25 15. The method of Claim 14, wherein the disorder or disease is selected from the group consisting of the infertility, prostate cancer and benign prostate hyperplasia (BPH).
16. A method of contraception in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
- 30 17. A method of treating a condition selected from the group consisting of the infertility, prostate cancer and benign prostate hyperplasia (BPH) in a

subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.

5 18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 7.

19. A pharmaceutical composition made by mixing a compound of Claim 7 and a pharmaceutically acceptable carrier.

10 20. A process for making a pharmaceutical composition comprising mixing a compound of Claim 7 and a pharmaceutically acceptable carrier.

15 21. A method of treating a disorder or disease which respond to antagonism of the GnRH in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 18.

20 22. The method of Claim 21, wherein the disorder or disease is selected from the group consisting of the infertility, prostate cancer and benign prostate hyperplasia (BPH).

23. A method of contraception in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 7.

25 24. A method of treating a condition selected from the group consisting of the infertility, prostate cancer and benign prostate hyperplasia (BPH) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 7.

30 25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 10.

26. A pharmaceutical composition made by mixing a compound of Claim 10 and a pharmaceutically acceptable carrier.

5 27. A process for making a pharmaceutical composition comprising mixing a compound of Claim 10 and a pharmaceutically acceptable carrier.

10 28. A method of treating a disorder or disease which respond to antagonism of the GnRH in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 25.

29. The method of Claim 28, wherein the disorder or disease is selected from the group consisting of the infertility, prostate cancer and benign prostate hyperplasia (BPH).

15 30. A method of contraception in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 10.

20 31. A method of treating a condition selected from the group consisting of the infertility, prostate cancer and benign prostate hyperplasia (BPH) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 10.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/048112 A3(51) International Patent Classification⁷: C07D 215/22,
471/04, 495/04, A61K 31/47, 31/435, A61P 15/00, 35/00
// (C07D 471/04, 231:00, 221:00) (C07D 495/04, 333:00,
221:00)

(21) International Application Number: PCT/US01/48119

(22) International Filing Date:
11 December 2001 (11.12.2001)



(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/254,827 12 December 2000 (12.12.2000) US
09/992,785 14 November 2001 (14.11.2001) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
22 August 2002(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL,
INC. [US/US]; US Route 202, Raritan, NJ 08869-0602
(US).(72) Inventors: SUI, Zhihua; 11 Running Brook Circle, Flem-
ington, NJ 08822 (US). MACIELAG, Mark; 8 Seneca
Trail, Branchburg, NJ 08876 (US). LANTER, James, C.;
3 Albion Court, Flemington, NJ 08822 (US).(74) Agents: JOHNSON, Philip, S. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, NJ 08933
(US).For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(54) Title: 7-HETEROCYCLYL QUINOLINE AND THIENO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS ANTAGONISTS
OF GONADOTROPIN RELEASING HORMONE

(57) Abstract: The present invention is directed to novel 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives of the general formula (I) or (II), wherein all variables are as herein defined, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions associated with gonadotropin releasing hormone (GnRH). The compounds of the invention are antagonists of GnRH, useful in the treatment of the infertility, prostate cancer, benign prostate hyperplasia (BPH) and as contraceptives.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/48119

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D215/22 C07D471/04 C07D495/04 A61K31/47 A61K31/435
 A61P15/00 A61P35/00 //(C07D471/04, 231:00, 221:00),
 (C07D495/04, 333:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 14682 A (CHOH NOBUO ; FURUYA SHUICHI (JP); SASAKI SATOSHI (JP); TAKEDA CHEMI) 24 April 1997 (1997-04-24) cited in the application page 1-2; example 3 ---	1-6, 11-17
X	US 6 015 789 A (FURUYA SHUICHI ET AL) 18 January 2000 (2000-01-18) Compound 7:6 table 59	1-6, 11-17
X	Compounds (X) tables 5,6,8-10 ---	7-10, 18-31
X	WO 95 28405 A (KATO KOICHI ; CHOH NOBUO (JP); FURUYA SHUICHI (JP); HINUMA SHUJI (J) 26 October 1995 (1995-10-26) tables 12,14-16 -----	7-10, 18-31

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

4 June 2002

Date of mailing of the international search report

12 June 2002 (12.06.02)

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Fritz, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/48119

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9714682	A	24-04-1997	AU 7333496 A	07-05-1997
			CN 1200114 A	25-11-1998
			EP 0876349 A1	11-11-1998
			WO 9714682 A1	24-04-1997
			JP 9169735 A	30-06-1997
			US 6087503 A	11-07-2000
			US 5807869 A	15-09-1998
<hr/>				
US 6015789	A	18-01-2000	AU 2407997 A	19-11-1997
			CA 2250908 A1	06-11-1997
			EP 0906115 A1	07-04-1999
			WO 9740846 A1	06-11-1997
			JP 10045625 A	17-02-1998
<hr/>				
WO 9528405	A	26-10-1995	AU 697472 B2	08-10-1998
			AU 2223995 A	10-11-1995
			AU 713116 B2	25-11-1999
			AU 8316998 A	05-11-1998
			BR 9501736 A	14-11-1995
			CA 2186124 A1	26-10-1995
			CN 1146206 A	26-03-1997
			CZ 9603028 A3	14-05-1997
			EP 0756599 A1	05-02-1997
			FI 964195 A	17-12-1996
			FI 20012326 A	28-11-2001
			HU 76320 A2	28-08-1997
			JP 8295693 A	12-11-1996
			WO 9528405 A1	26-10-1995
			NO 964434 A	18-10-1996
			NZ 283813 A	25-11-1998
			NZ 332206 A	29-06-2001
			PL 316796 A1	17-02-1997
			RU 2150470 C1	10-06-2000
			TW 449600 B	11-08-2001
			US 6187788 B1	13-02-2001
			US 5817819 A	06-10-1998
			US 6180792 B1	30-01-2001
			US 6048863 A	11-04-2000
			AU 4632796 A	27-08-1996
			BR 9600341 A	15-09-1998
			CA 2211969 A1	15-08-1996
			CN 1173868 A ,B	18-02-1998
			EP 0808317 A1	26-11-1997
			JP 9169768 A	30-06-1997
			WO 9624597 A1	15-08-1996
			RU 2158739 C2	10-11-2000
			TR 960748 A2	21-08-1996

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/48119

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-6,11-17

Compounds of formula (I), compositions thereof, a process for their preparation and methods of treatment involving a compound (I).

2. Claims: 7-20,18-31

Compounds of formula (II), compositions thereof, a process for their preparation and methods of treatment involving a compound (II).